Close Menu

investment analyst coverage

Evercore said that Hologic's recent divestiture of its blood screening business limits near-term EPS growth; Piper, however, is looking forward to 2018.

The bank said that although it is forecasting a 17 percent stronger flu season this year, Quidel's influenza sales are only likely to rise 10 percent.

The investment bank said Veracyte's negative classifier tests are of significant value to healthcare providers and payors.

Pages